2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Brain Neoplasms
12
Cognitive Dysfunction
4
Radiation Injuries
3
Neoplasms
3
Multiple Myeloma
3
Glioma
3
Breast Neoplasms
3
Lymphoma, B-Cell
2
Lymphoma
2
Glioblastoma
2
Fatigue
2
Colorectal Neoplasms
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Stroke
1
Sarcoma
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parkinson Disease
1
Osteosarcoma
1
Oligodendroglioma
1
Neurotoxicity Syndromes
1
Neurofibromatosis 1
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Sorafenib
222
lenvatinib
147
Bevacizumab
131
Nivolumab
87
atezolizumab
81
pembrolizumab
74
Radiosurgery
71
durvalumab
63
sintilimab
61
Oxaliplatin
60
Fluorouracil
56
Doxorubicin
47
tislelizumab
46
apatinib
45
Radiofrequency Ablation
44
Hepatectomy
43
camrelizumab
41
Leucovorin
41
Radiotherapy
40
tremelimumab
37
Magnetic Resonance Spectroscopy
36
regorafenib
34
Capecitabine
30
Immune Checkpoint Inhibitors
29
Folfox protocol
29
Cisplatin
28
cabozantinib
26
Gemcitabine
26
Cyclophosphamide
26
Ipilimumab
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Neuropsychological Tests
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled